We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+0.48%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$103M
Cap. Flow
+$76.4M
Cap. Flow %
7.03%
Top 10 Hldgs %
55.27%
Holding
75
New
18
Increased
23
Reduced
22
Closed
7

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$24.3M
2
UNH icon
UnitedHealth
UNH
+$23.2M
3
RVTY icon
Revvity
RVTY
+$19.9M
4
AVTR icon
Avantor
AVTR
+$19.2M
5
ILMN icon
Illumina
ILMN
+$16.1M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.9M
2
HQY icon
HealthEquity
HQY
+$18.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$18.5M
4
NTRA icon
Natera
NTRA
+$15.2M
5
GSK icon
GSK
GSK
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.21%
2 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
26
Protagonist Therapeutics
PTGX
$8.75B
$15.3M 1.41%
277,316
-269,800
-49% -$12.9M
DVAX
27
DELISTED
Dynavax Technologies
DVAX
$11.9M 1.09%
+1,197,189
New +$12.6M
MIRM icon
28
Mirum Pharmaceuticals
MIRM
$6.89B
$11.8M 1.09%
+232,175
New +$10.3M
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.37B
$10.8M 1%
1,207,638
-964,798
-44% -$8.98M
EOLS icon
30
Evolus
EOLS
$394M
$10.8M 0.99%
+1,170,311
New +$12M
HUM icon
31
Humana
HUM
$46.7B
$10.7M 0.98%
43,620
+15,650
+56% +$3.9M
GERN icon
32
Geron
GERN
$911M
$10.3M 0.95%
+7,320,174
New +$10.4M
GMED icon
33
Globus Medical
GMED
$10.4B
$10M 0.92%
169,643
-23,250
-12% -$1.5M
ICLR icon
34
Icon
ICLR
$12.8B
$9.39M 0.86%
64,587
+53,747
+496% +$7.62M
NAMS icon
35
NewAmsterdam Pharma
NAMS
$3.47B
$7.51M 0.69%
414,430
+133,479
+48% +$2.43M
ELV icon
36
Elevance Health
ELV
$81.9B
$7.38M 0.68%
18,962
+3,264
+21% +$1.31M
REGN icon
37
Regeneron Pharmaceuticals
REGN
$68.8B
$6.96M 0.64%
+13,254
New +$7.4M
MRUS
38
DELISTED
Merus
MRUS
$6.89M 0.63%
130,924
+60,595
+86% +$2.85M
MOH icon
39
Molina Healthcare
MOH
$10.3B
$6.14M 0.56%
20,600
-3,135
-13% -$984K
TMO icon
40
Thermo Fisher Scientific
TMO
$211B
$5.55M 0.51%
+13,685
New +$5.72M
EWTX icon
41
Edgewise Therapeutics
EWTX
$4.39B
$5.15M 0.47%
+392,739
New +$5.66M
DHR icon
42
Danaher
DHR
$135B
$4.63M 0.43%
+23,449
New +$4.55M
LQDA icon
43
Liquidia Corp
LQDA
$7.67B
$4.47M 0.41%
358,828
+208,348
+138% +$3.08M
GKOS icon
44
Glaukos
GKOS
$9.02B
$3.25M 0.3%
31,496
-127,461
-80% -$12M
ZBIO
45
Zenas BioPharma
ZBIO
$1.92B
$3.15M 0.29%
325,479
-120,109
-27% -$1.17M
NKTR icon
46
Nektar Therapeutics
NKTR
$2.39B
$2.97M 0.27%
+115,000
New +$1.29M
ALEC icon
47
Alector
ALEC
$164M
$2.78M 0.26%
1,986,072
+1,368,654
+222% +$1.71M
AMRN
48
Amarin Corp
AMRN
$284M
$2.71M 0.25%
167,276
-2,684
-2% -$30.2K
MNKD icon
49
MannKind Corp
MNKD
$1.28B
$2.61M 0.24%
697,710
– –
ETNB
50
DELISTED
89bio
ETNB
$2.32M 0.21%
235,990
-67,741
-22% -$561K
1
2
3

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Eversept Partners held 75 positions worth $1.09B, up 10% from $985M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Eversept Partners deployed $76.4M of net new capital in Q2 2025, opening 18 new positions and adding to 23 existing holdings. Its largest new stake was UnitedHealth: 60,736 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was HCA Healthcare, an estimated $18.9M trimmed.

  • Eversept Partners's largest Q2 2025 buy was UnitedHealth: 60,736 shares worth $18.9M.
  • Eversept Partners added most to Vaxcyte in Q2 2025, an estimated $24.3M increase.
  • Eversept Partners's biggest Q2 2025 reduction was HCA Healthcare, cutting an estimated $18.9M.
  • Eversept Partners fully exited Neurocrine Biosciences in Q2 2025, selling an estimated $18.5M.
  • Eversept Partners's ten largest holdings make up 55% of its $1.09B portfolio in Q2 2025.
  • Eversept Partners opened 18 new positions and closed 7 in Q2 2025.
  • Eversept Partners's portfolio value rose 10% quarter-over-quarter to $1.09B.

Based on Eversept Partners's 13F filing for Q2 2025, filed 14 Aug 2025.